Adj. EBIT -29% vs FactSet consensus; FX adj sales -11% y-o-y Estimates to come down 8-10% on slower ...
Redeye provides an initial take following the release of Optomed’s Q2 2025 report.
DT’s Q2 revenue was slightly higher than expected, however the EUR 1.
Etteplan’s H1 was disappointing, with the escalation of the trade war causing demand to weaken furth...
Redeye comments on G5’s Q2-results where results were weaker than expected, partly driven by USD/SEK...
Redeye updates on Embracer ahead of Q1-results (due 14 August) where we forecast a slow start to 202...
New full year guidance for adjusted EBITDA in core businesses’ is EUR 16–20m in 2025 (previously EUR...
There were no surprises in Etteplan’s Q2 figures, since the company earlier issued a profit warning ...
SRV reports its Q2 figures on 8th of August. We continue to expect volume decline for the quarter, a...
Raute reports Q2 results on Aug 12. This year will set another earnings record, while the focus now ...
Redeye comments briefly on Insplorion’s recent update on strategic development and ongoing key initi...
NoHo Partners' Q2 2025 results fell short of Vara Research consensus expectations, mainly due to the...
The last of the non-core assets was divested in July.
Six Freemelt ONE orders and sales of SEK 19m mark record quarter Estimates intact, deviation from AB...
Q2 pre-tax profit came in at DKK 115m, DKK 19m (20%) above our estimate.
